source
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
- RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACRare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.